Horan Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Horan Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-170	Closed	-$95K	–	234
2020 Q3	$95K	Buy	+170	New	+$103K	0.05%	119
2020 Q1	–	Sell	-170	Closed	-$64K	–	214
2019 Q4	$64K	Hold	170	–	–	0.04%	134
2019 Q3	$47K	Buy	+170	New	+$50.3K	0.03%	147
2019 Q2	–	Sell	-170	Closed	-$70K	–	204
2019 Q1	$70K	Buy	+170	New	+$70K	0.04%	124

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Horan Capital Advisors's REGN Position: Q4 2020 in Review

Horan Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 170 shares — an estimated $95K sold.

Horan Capital Advisors first reported a position in REGN in Q1 2019 and held it in 4 quarters. The position peaked at $95K in Q3 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

Horan Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Horan Capital Advisors sold 170 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $95K.
Horan Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Horan Capital Advisors's Regeneron Pharmaceuticals position peaked at $95K in Q3 2020.
903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Horan Capital Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.